Tk. Jha et al., RANDOMIZED CONTROLLED TRIAL OF AMINOSIDINE (PAROMOMYCIN) UPSILON-SODIUM STIBOGLUCONATE FOR TREATING VISCERAL LEISHMANIASIS IN NORTH BIHAR, INDIA, BMJ. British medical journal, 316(7139), 1998, pp. 1200-1205
Objectives: To assess the efficacy and tolerability of aminosidine com
pared with sodium stibogluconate for treating visceral leishmaniasis.
Design: Randomised, unblinded, controlled trial with 180 day follow up
. Setting: Kala-Azar Research Centre, Brahmpura, Muzaffarpur, Bihar, I
ndia. Subjects: People of either sex aged 6-50 years with symptoms and
signs suggestive of visceral leishmaniasis (fever, loss of appetite,
enlarged spleen). with leishmania amastigotes detected in Giemsa stain
ed aspirates of spleen or bone marrow. Interventions: Aminosidine at t
hree daily doses (12, 16, and 20 mg/kg) for 21 days and sodium stibogl
uconate 20 mg/kg/day for 30 days. Main outcome measures: Laboratory me
asures of efficacy: parasite count, haemoglobin concentration, white c
ell count platelet count, serum albumin concentration. Clinical measur
es of efficacy: spleen size, fever, body weight, and liver size. Measu
res of safety: liver and renal function tests, reports of adverse even
ts. Results: Of the 120 patients enrolled (30 per treatment arm), 119
completed treatment and follow up. Cure at end of follow up was achiev
ed in 23 (77%), 28 (93%), and 29 (97%) patients treated with 12, 16, a
nd 20 mg aminosidine/kg/day respectively, and in 19 (63%) patients giv
en sodium stibogluconate. At 16 and 20 mg/kg/day, aminosidine was sign
ificantly more active than sodium stibogluconate in both clinical and
laboratory measures of efficacy. No significant clinical or laboratory
toxicity occurred in any treatment group. Conclusions: A 21 day cours
e of aminosidine 16 or 20 mg/kg/day should be considered as first line
treatment for visceral leishmaniasis in Bihar.